{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:49:04Z","timestamp":1779101344726,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T00:00:00Z","timestamp":1223510400000},"content-version":"vor","delay-in-days":2139,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:p>\n                    <jats:bold>OBJECTIVES:<\/jats:bold>\n                    To assess whether cilostazol, a phosphodiesterase III inhibitor, improves treadmill and community\u2010based walking ability and health\u2010related quality of life (HQL) in patients with intermittent claudication resulting from peripheral arterial disease (PAD).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>DESIGN:<\/jats:bold>\n                    Retrospective meta\u2010analysis of data pooled from six Phase 3, multicenter, double\u2010blind, placebo\u2010controlled, parallel\u2010group, randomized studies.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>SETTING:<\/jats:bold>\n                    Patients were recruited from outpatient ambulatory medical care facilities.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PARTICIPANTS:<\/jats:bold>\n                    Patients' (n = 1,751) mean age \u00b1 standard deviation was 65 \u00b1 9, and they had a history of PAD for 6 months or longer and an ankle brachial index (ABI) of 0.90 or less.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>INTERVENTION:<\/jats:bold>\n                    Cilostazol 50 mg bid or 100 mg bid for 12, 16, or 24 weeks.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>MEASUREMENTS:<\/jats:bold>\n                    ABI; maximal walking distance (MWD); pain\u2010free walking distance on a graded and constant\u2010load treadmill; and HQL, measured using the Walking Impairment Questionnaire (WIQ) and the Medical Outcomes Study Short Form\u201036 (SF\u201036).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    Maximal treadmill walking distance improved more in both cilostazol groups than in the placebo group (both\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .0001). WIQ and SF\u201036 physical summary scores improved significantly more with cilostazol than with placebo (for instance, WIQ distance score,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .0001 and SF\u201036 physical summary score,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .0001, comparing persons taking cilostazol with controls). Improved MWD correlated with improvements in WIQ (correlation with distance score,\n                    <jats:italic>r<\/jats:italic>\n                    = 0.34,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .0001) and SF\u201036 physical summary scores (\n                    <jats:italic>r<\/jats:italic>\n                    = 0.29,\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .0001).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSIONS:<\/jats:bold>\n                    Treatment with cilostazol was associated with greater improvements in community\u2010based walking ability and HQL in patients with intermittent claudication than treatment with placebo. These improvements correlated with increased MWD. This analysis of effects of cilostazol on improving walking ability in persons with claudication is the first cilostazol study focused on community\u2010based measures of functional status and HQL. Questionnaires assessing walking ability and HQL provide important patient\u2010based information about clinical outcomes of claudication therapy.\n                  <\/jats:p>","DOI":"10.1046\/j.1532-5415.2002.50604.x","type":"journal-article","created":{"date-parts":[[2004,12,27]],"date-time":"2004-12-27T02:57:41Z","timestamp":1104116261000},"page":"1939-1946","source":"Crossref","is-referenced-by-count":186,"title":["Effect of Cilostazol on Treadmill Walking, Community\u2010Based Walking Ability, and Health\u2010Related Quality of Life in Patients with Intermittent Claudication Due to Peripheral Arterial Disease: Meta\u2010Analysis of Six Randomized Controlled Trials"],"prefix":"10.1111","volume":"50","author":[{"given":"Judith G.","family":"Regensteiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"John E.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter J.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William P.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Hiatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.17.2041"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.12.1942"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(98)70357-X"},{"key":"e_1_2_6_5_2","first-page":"I\u201312","article-title":"Two doses of cilostazol versus placebo in the treatment of claudication: Results of a randomized, multicenter trial [abstract 59].","volume":"95","author":"Strandness DE","year":"1998","journal-title":"Circulation"},{"key":"e_1_2_6_6_2","unstructured":"Data on file. Otsuka America Pharmaceutical Inc."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00569-6"},{"key":"e_1_2_6_8_2","first-page":"142","article-title":"Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease.","volume":"2","author":"Regensteiner JG","year":"1990","journal-title":"J Vasc Med Biol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(05)80040-0"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(98)70034-5"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03430070073033"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008483-198812200-00005"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1249\/00005768-199104000-00003"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008483-199901000-00006"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(00)70071-1"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199303000-00006"},{"key":"e_1_2_6_17_2","volume-title":"SF\u201036 Physical and Mental Health Summary Scales: A User's Manual","author":"Ware JE","year":"1994"},{"key":"e_1_2_6_18_2","first-page":"AS264","article-title":"Comparison of methods for the scoring and statistical analysis of SF\u201036 health profile and summary measures: Summary of results from the Medical Outcomes Study.","volume":"33","author":"Ware JE","year":"1995","journal-title":"Med Care"},{"key":"e_1_2_6_19_2","volume-title":"Statistical Methods for Meta\u2010Analysis","author":"Hedges LV","year":"1985"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.81.2.602"},{"key":"e_1_2_6_21_2","volume-title":"SF\u201036 Physical and Mental Health Summary Scales: A Manual for Users of Version 1","author":"Ware JE","year":"2001"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199915020-00003"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1532-5415.2002.50604.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1532-5415.2002.50604.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:48:35Z","timestamp":1762195715000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1046\/j.1532-5415.2002.50604.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1046\/j.1532-5415.2002.50604.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1532-5415.2002.50604.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}